Milestone Pharmaceuticals Inc. Operating Lease, Expense
Milestone Pharmaceuticals Inc. (MIST) reported Operating Lease, Expense of $668.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-03-20
- Milestone Pharmaceuticals Inc. operating lease, expense for the quarter ending 2020-12-31 was $78.00K, a 4.00% increase year-over-year.
- Milestone Pharmaceuticals Inc. operating lease, expense for the quarter ending 2019-12-31 was $75.00K.
- Milestone Pharmaceuticals Inc. operating lease, expense for the quarter ending 2019-09-30 was $124.00K.
- Milestone Pharmaceuticals Inc. operating lease, expense for the quarter ending 2019-06-30 was $34.00K.
- Milestone Pharmaceuticals Inc. operating lease, expense for fiscal 2025 was $668.00K, a 4.16% decline from fiscal 2024.
- Milestone Pharmaceuticals Inc. operating lease, expense for fiscal 2024 was $697.00K, a 2.35% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. operating lease, expense for fiscal 2023 was $681.00K, a 38.98% increase from fiscal 2022.
- Milestone Pharmaceuticals Inc. operating lease, expense for fiscal 2022 was $490.00K, a 56.05% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $668.00K 10-K · filed 2026-03-20 | |||
| 2024-12-31 | $697.00K 10-K · filed 2026-03-20 | |||
| 2023-12-31 | $681.00K 10-K · filed 2025-03-13 | |||
| 2022-12-31 | $490.00K 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $314.00K 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $318.00K 10-K · filed 2022-03-24 | ||
| 2020-09-30 | $240.00K 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | $75.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $199.00K derived: sum of 2 quarters · filed 2020-11-13 | $233.00K derived: sum of 3 quarters · filed 2020-11-13 | $277.00K 10-K/A · filed 2020-10-23 |
| 2019-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $158.00K derived: sum of 2 quarters · filed 2020-11-13 | $202.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $78.00K 10-Q · filed 2019-08-13 | ||
| 2019-03-31 | $44.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |